Mepolizumab (Nucala)
Revision as of 18:19, 6 September 2015 by Jwarner (talk | contribs) (Created page with "=General information= Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). =Preliminary data= ==Hypereosinophilic syndrome (HES)== # Rothenb...")
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Preliminary data
Hypereosinophilic syndrome (HES)
- Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. link to original article PubMed